Background: Different scoring systems have been developed to determine the severity of atopic dermatitis (AD); the SCORAD (Scoring Atopic Dermatitis) and EASI (Eczema Area and Severity Index) are among the best-validated scoring systems. Objective: The aim of this study was to produce a rational quality control for routine clinical use by using the modern facilities of digital imaging. Methods: 63 AD patients were scored by a single person at each visit using the SCORAD and EASI scoring methods. Images were taken and rated by two non-dermatology physicians trained in the scoring system. In addition, blood samples were taken for the determination of total IgE, eosinophils and eosinophilic cationic protein. Results: The EASI score established from the digital images, hereby named ‘EASIdig’, correlated at all visits with the results of the SCORAD and EASI. Together with immunological parameters, they also reflected changes of disease severity during the 3 time points. Conclusion: The digital evaluation of the EASI is a reliable tool for the digital assessment of severity and extent of AD.

1.
Oakes RC, Cox AD, Burgdorf WH: Atopic dermatitis. A review of diagnosis, pathogenesis, and management. Clin Pediatr (Phila) 1983;22:467–475.
2.
Wuthrich B: Serum IgE in atopic dermatitis: relationship to severity of cutaneous involvement and course of disease as well as coexistence of atopic respiratory diseases. Clin Allergy 1978;8:241–248.
3.
Kemeny DM, Noble A, Holmes BJ, Diaz-Sanchez D, Lee TH: The role of CD8+ T cells in immunoglobulin E regulation. Allergy 1995;50:9–14.
4.
Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A: Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10–19.
5.
Vourc’h-Jourdain M, Barbarot S, Taieb A, Diepgen T, Ambonati M, Durosier V, Sibaud V, Stalder JF: Patient-oriented SCORAD: a self-assessment score in atopic dermatitis. A preliminary feasibility study. Dermatology 2009;218:246–251.
6.
Rajka G, Langeland T: Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989;144:13–14.
7.
Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, Oranje A, Deleuran M, Cambazard F, Svensson A, Simon D, Benfeldt E, Reunala T, Mazereeuv J, Boralevi F, Kunz B, Misery L, Mortz CG, Darsow U, Gelmetti C, Diepgen T, Ring J, Moehrenschlager M, Gieler U, Taieb A: Patient-oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in europe. Allergy 201166:1114–1121.
8.
Wolkerstorfer A, de Waard van der Spek FB, Glazenburg EJ, Mulder PG, Oranje AP: Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol 1999;79:356–359.
9.
Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schoepf E, Thestrup-Pedersen K, Van Der Valk PG, Bos JD: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788–794.
10.
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M: The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI evaluator group. Exp Dermatol 2001;10:11–18.
11.
Whited JD, Hall RP, Simel DL, Foy ME, Stechuchak KM, Drugge RJ, Grichnik JM, Myers SA, Horner RD: Reliability and accuracy of dermatologists’ clinic-based and digital image consultations. J Am Acad Dermatol 1999;41:693–702.
12.
Baumeister T, Weistenhofer W, Drexler H, Kutting B: Spoilt for choice – evaluation of two different scoring systems for early hand eczema in teledermatological examinations. Contact Dermatitis 2010;62:241–247.
13.
Nordal EJ, Moseng D, Kvammen B, Lochen ML: A comparative study of teleconsultations versus face-to-face consultations. J Telemed Telecare 2001;7:257–265.
14.
Taylor P: An assessment of the potential effect of a teledermatology system. J Telemed Telecare 2000;6(suppl 1):S74–76.
15.
Rajbhandari SM, Harris ND, Sutton M, Lockett C, Eaton S, Gadour M, Tesfaye S, Ward JD: Digital imaging: an accurate and easy method of measuring foot ulcers. Diabet Med 1999;16:339–342.
16.
Warshaw EM, Lederle FA, Grill JP, Gravely AA, Bangerter AK, Fortier LA, Bohjanen KA, Chen K, Lee PK, Rabinovitz HS, Johr RH, Kaye VN, Bowers S, Wenner R, Askari SK, Kedrowski DA, Nelson DB: Accuracy of teledermatology for pigmented neoplasms. J Am Acad Dermatol 2009;61:753–765.
17.
Martin LB, Kita H, Leiferman KM, Gleich GJ: Eosinophils in allergy: role in disease, degranulation, and cytokines. Int Arch Allergy Immunol 1996;109:207–215.
18.
Bieber T: Atopic dermatitis. N Engl J Med 2008;358:1483–1494.
19.
Laske N, Niggemann B: Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol 2004;15:86–88.
20.
Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271–277.
21.
Iju M: Study on the genesis of atopic dermatitis – atopic dermatitis and IgE. Hokkaido Igaku Zasshi 1985;60:806–833.
22.
Wüthrich B: Zur Immunpathologie der Neurodermitis constitutionalis. Eine klinisch-immunologische Studie mit besonderer Berücksichtigung der Immunglobuline E und der spezifischen Reagine im zeitlichen Verlauf. Bern, Huber, 1975.
23.
Wüthrich B, Schmid-Grendelmeier P: The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (‘extrinsic’) and the nonallergic (‘intrinsic’) AEDS. J Investig Allergol Clin Immunol 2003;13:1–5.
24.
Ezzat M, Hasan Z, Shaheen K: Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol 2011;25:334–339.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.